Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

CatalYm

company

About

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Details

Last Funding Type
Series C
Last Funding Money Raised
€50M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active
Legal Name
CatalYm GmbH

CatalYm is a biotechnology company committed to developing innovative immunotherapies for cancer patients. CatalYm has identified GDF-15 as a central regulator of the immune system in the tumor microenvironment and translates the therapeutic potential of neutralizing GDF-15 into meaningful clinical responses for patients with solid tumors. CatalYm’s CTL-002 program is poised to demonstrate clinical proof-of-concept in multiple solid tumor indications and has the potential to expand the treatment horizon for current and future immunotherapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€100M
CatalYm has raised a total of €100M in funding over 2 rounds. Their latest funding was raised on Nov 22, 2022 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 22, 2022 Series C €50M 8 Brandon Capital Partners
Jeito Capital
Detail
Nov 19, 2020 Series B €50M 6 Vesalius Biocapital Partners Detail
Aug 5, 2016 Seed 1 Detail

Investors

Number of Lead Investors
Number of Investors
3
9
CatalYm is funded by 9 investors. Brandon Capital Partners and Jeito Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Brandon Capital Partners Yes Series C
Jeito Capital Yes Series C
Bayern Kapital Series C
BioGeneration Ventures Series C
coparion Series C
Forbion Capital Partners Series C
Novartis Venture Fund Series C
Vesalius Biocapital Partners Series C
Wachstumsfonds Bayern Series B

Employee Profiles

Number of Employee Profiles
13
CatalYm has 13 current employee profiles, including Board member John Haurum
Board member
Board member
Board member
Executive
Board member